Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.

This meta-analysis examined the efficacy of different dosing regimens containing rituximab (RTX) in treating pemphigus. The analysis included 578 patients with pemphigus from 30 studies. Seventy-six percent of patients achieved complete remission (CR) after 1 cycle of RTX. Mean time to remission was 5.8 months, with a remission duration of 14.5 months and a 40% relapse rate. Eighteen patients (3.3%) developed serious adverse effects. The pooled estimate showed no significant differences in CR and relapse rates between patients treated with high-dose (near or ≥ 2,000 mg/cycle) vs. low-dose (< 1,500 mg/cycle) RTX. In the fully adjusted analysis, high-dose RTX was associated with longer duration of CR compared with low-dose RTX. No superiority of lymphoma protocol over rheumatoid arthritis or high-dose RTX over low-dose RTX was shown in other outcomes. RTX treatment is efficacious and well-tolerated in treating pemphigus. High-dose RTX treatment may lead to longer duration of remission. However, the choice of optimal regimen depends on the overall condition of the individual patient.

[1]  Li-Fang Wang,et al.  First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. , 2014, Acta dermato-venereologica.

[2]  N. Shear,et al.  Durable remission of pemphigus with a fixed-dose rituximab protocol. , 2014, JAMA dermatology.

[3]  B. Bonnekoh,et al.  Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  H. Koga,et al.  Clinical and immunological outcomes of high‐ and low‐dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer‐blinded study , 2014, The British journal of dermatology.

[5]  E. Papadavid,et al.  Pilot Study of 19 Patients with Severe Pemphigus: Prophylactic Treatment with Rituximab Does Not Appear to be Beneficial , 2014, Dermatology.

[6]  Hyun Hee Cho,et al.  Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  E. Houivet,et al.  Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. , 2013, Journal of the American Academy of Dermatology.

[8]  S. Khezri,et al.  Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial , 2013, International journal of dermatology.

[9]  S. Greenberger,et al.  Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases , 2013, The Journal of dermatological treatment.

[10]  J. Roujeau,et al.  Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response , 2013, Science Translational Medicine.

[11]  E. Hodak,et al.  Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. , 2013, Journal of the American Academy of Dermatology.

[12]  H. Koga,et al.  Efficacy and safety of rituximab treatment in Indian pemphigus patients , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  A. Ahmed,et al.  Rituximab in the Treatment of Pemphigus Vulgaris , 2012, Dermatology and Therapy.

[14]  D. Allison,et al.  A Guide to Rational Dosing of Monoclonal Antibodies , 2012, Clinical Pharmacokinetics.

[15]  R. Corona,et al.  Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. , 2012, Journal of the American Academy of Dermatology.

[16]  M. Meurer,et al.  Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[17]  P. Bernard,et al.  Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. , 2012, Journal of the American Academy of Dermatology.

[18]  K. Propert,et al.  Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. , 2012, Archives of dermatology.

[19]  R. Eming,et al.  Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult‐to‐treat pemphigus vulgaris , 2012, The British journal of dermatology.

[20]  W. Christen,et al.  Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy , 2012, The British journal of dermatology.

[21]  M. Jonkman,et al.  Low‐dose rituximab is effective in pemphigus , 2012, The British journal of dermatology.

[22]  M. Kasperkiewicz,et al.  Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients , 2012, The British journal of dermatology.

[23]  G. Mufti,et al.  Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. , 2011, Journal of the American Academy of Dermatology.

[24]  M. Miteva.  Faculty Opinions recommendation of Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. , 2011 .

[25]  H. Kim,et al.  Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 Patients , 2011, Dermatology.

[26]  S. Kim,et al.  Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients , 2011, The British journal of dermatology.

[27]  R. Feldman,et al.  Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses , 2011, Expert review of clinical immunology.

[28]  D. Murrell,et al.  A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. , 2011, Journal of the American Academy of Dermatology.

[29]  S. Grover.  SCORING SYSTEMS IN PEMPHIGUS , 2011, Indian journal of dermatology.

[30]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[31]  D. Zillikens,et al.  Immunogenicity of rituximab in patients with severe pemphigus. , 2009, Clinical immunology.

[32]  D. Zillikens,et al.  Rituximab in Severe Pemphigus , 2009, Annals of the New York Academy of Sciences.

[33]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[34]  D. Zillikens,et al.  Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins , 2007, The British journal of dermatology.

[35]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[36]  R. Corona,et al.  Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. , 2007, Archives of dermatology.

[37]  P. Foley,et al.  Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open‐label pilot study in five patients , 2007, The British journal of dermatology.

[38]  D. Fanoni,et al.  Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab) , 2007, Dermatology.

[39]  C. Varotti,et al.  Treatment of refractory pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab): Five cases , 2007, The Journal of dermatological treatment.

[40]  J. Sundharam.  Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. , 2006, Indian journal of dermatology, venereology and leprology.

[41]  T. Krieg,et al.  Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus , 2005, The British journal of dermatology.

[42]  S. Imamura,et al.  History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan , 2003, Archives of Dermatological Research.

[43]  J. Bystryn,et al.  Patterns of remission in pemphigus vulgaris. , 2000, Journal of the American Academy of Dermatology.

[44]  R. Bergman,et al.  A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab , 2013, Archives of Dermatological Research.

[45]  C. Cheyda,et al.  Adjuvant rituximab in the treatment of pemphigus vulgaris : a phase II clinical trial , 2013 .

[46]  D. Zillikens,et al.  Current therapy of the pemphigus group. , 2012, Clinics in dermatology.

[47]  R. Eming,et al.  Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. , 2007, European journal of dermatology : EJD.